Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel versus clopidogrel PK/PD comparison in low- versus higher-body-weight aspirin-treated stable coronary artery disease patients
NL-OMON32918Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Trial of prasugrel, clopidogrel and aspirin in coronary arteriosclerosis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary pharmacodynamic endpoint. Planned start Dec 2009; status: withdrawn.
02
Drugs
prasugrelclopidogrelaspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON32918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32918.